Galafod

Baird has upgraded Amicus Therapeutics, Inc. (NASDAQ: FOLD) to Outperform, driven by the removal of two key overhangs in the form of regulatory clarity for Galafold in the United States and strengthening of the balance sheet. Further, the brokerage raised its target price by $3 to $10 on inclusion...